The 100 Days Mission Scorecard 3.0, developed in partnership with Impact Global Health, provides a data‑driven assessment of global readiness across diagnostics, therapeutics and vaccines.
New data shows:
- Limited progress has been made, with the ecosystem remaining reactive and reliant on US funding.
- R&D funding has declined across most pathogens and product types (platform technologies remain resilient, but US Government funding dominated).
- Therapeutics represent a critical gap – there is declining funding and a contracting pipeline requiring immediate action.
- Pipeline stagnation is evident, and most candidates are arrested at phase 1 with progression limited to early-stage transitions.
- Alternative pathways and R&D enablers are underutilised, constraining acceleration opportunities.